Minghui Li1, Kai Sun, Lisbeth A Welniak, William J Murphy. 1. University of Nevada, University of Nevada School of Medicine, Department of Microbiology and Immunology, Mail Stop 199, Reno, NV 89557, USA.
Abstract
BACKGROUND: Allogeneic hematopoietic stem cell transplantation offers great promise for the treatment of a variety of diseases including malignancies and other diseases of hematopoietic origin. However, morbidity and mortality due to graft-versus-host disease (GVHD) remain a major barrier to its application. OBJECTIVE: This review will provide an overview of the pathophysiology of GVHD and discuss the recent advances in GVHD management in both preclinical and clinical studies. METHODS: An extensive literature search on PubMed from 1995 to 2008 was performed. RESULTS/ CONCLUSION: There has been much progress in our understanding of GVHD and finding new means to control acute GVHD. While these approaches hold promise, as yet none has been able to replace the standard methods we may use routinely to decrease the incidence of the condition.
BACKGROUND: Allogeneic hematopoietic stem cell transplantation offers great promise for the treatment of a variety of diseases including malignancies and other diseases of hematopoietic origin. However, morbidity and mortality due to graft-versus-host disease (GVHD) remain a major barrier to its application. OBJECTIVE: This review will provide an overview of the pathophysiology of GVHD and discuss the recent advances in GVHD management in both preclinical and clinical studies. METHODS: An extensive literature search on PubMed from 1995 to 2008 was performed. RESULTS/ CONCLUSION: There has been much progress in our understanding of GVHD and finding new means to control acute GVHD. While these approaches hold promise, as yet none has been able to replace the standard methods we may use routinely to decrease the incidence of the condition.
Authors: H Khoury; A Kashyap; D R Adkins; R A Brown; G Miller; R Vij; P Westervelt; K Trinkaus; L T Goodnough; R J Hayashi; P Parker; S J Forman; J F DiPersio Journal: Bone Marrow Transplant Date: 2001-05 Impact factor: 5.483
Authors: T Kuroiwa; E Kakishita; T Hamano; Y Kataoka; Y Seto; N Iwata; Y Kaneda; K Matsumoto; T Nakamura; T Ueki; J Fujimoto; T Iwasaki Journal: J Clin Invest Date: 2001-06 Impact factor: 14.808
Authors: R A Nash; J H Antin; C Karanes; J W Fay; B R Avalos; A M Yeager; D Przepiorka; S Davies; F B Petersen; P Bartels; D Buell; W Fitzsimmons; C Anasetti; R Storb; V Ratanatharathorn Journal: Blood Date: 2000-09-15 Impact factor: 22.113
Authors: A Panoskaltsis-Mortari; P A Taylor; J S Rubin; A Uren; L A Welniak; W J Murphy; C L Farrell; D L Lacey; B R Blazar Journal: Blood Date: 2000-12-15 Impact factor: 22.113
Authors: H T Greinix; B Volc-Platzer; P Kalhs; G Fischer; A Rosenmayr; F Keil; H Hönigsmann; R M Knobler Journal: Blood Date: 2000-10-01 Impact factor: 22.113
Authors: L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon Journal: Cancer Res Date: 2000-09-15 Impact factor: 12.701